Innovative Leap in Obesity Treatment: Vivani Medical Initiates First-in-Human Trial of GLP-1 Implant in Australia In a transformative stride forward in the battle against obesity, Vivani Medical, Inc. (Nasdaq: VANI), a pioneering name in the biopharmaceutical domain, has commenced its groundbreaking first-in-human clinical trial of an exenatide implant in Australia. This initiative, dubbed LIBERATE-1, marks an extraordinary leap in the company’s mission to offer innovative, ultra long-acting drug implants that could potentially redefine the therapeutic landscape for overweight and obese individuals.Administered at two prestigious clinical centers in Australia, the LIBERATE-1 trial is set to scrutinize the ...
Vivani Medical, a pioneering biopharmaceutical company based in Alameda, California, has announced a significant breakthrough in the field of long-term drug implants. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) and lifted the clinical hold on NPM-119, Vivani s groundbreaking miniature long-term subdermal GLP-1 drug implant.The clearance comes as an exciting development for the company, as it opens doors for the initiation of LIBERATE-1, a Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of NPM-119, specifically exenatide. This trial aims to provide critical insights into the potential of the drug implant for ...
Pioneering the Future of Veterinary Medicine: Vivani Medical Announces Landmark Progress in Combatting Feline Obesity with Innovative OKV-119 Implant In a remarkable stride towards revolutionizing the realm of veterinary medicine, Vivani Medical, Inc. (Nasdaq: VANI), a cutting-edge biopharmaceutical company renowned for developing miniaturized, long-term drug implants, has heralded the publication of groundbreaking weight loss data. This pivotal research underscores the potential veterinary use of their novel product, the OKV-119, a miniature, subdermal exenatide drug implant. This breakthrough aims to treat feline obesity and diabetes, presenting a beacon of hope for pet owners and veterinarians alike.Headq...
Vivani Medical Reports First Quarter 2024 Financial Results and Provides Business UpdateALAMEDA, Calif. - Vivani Medical, Inc. (Nasdaq: VANI), a leading biopharmaceutical company specializing in the development of miniaturized, long-term drug implants, released its financial results for the first quarter of 2024 and provided an update on its business operations. The company s flagship product, NPM-115, aims to address chronic weight management in obese or overweight patients with multiple risk factors.Adam Mendelsohn, Ph.D., Chief Executive Officer of Vivani, expressed his satisfaction with the company s progress by stating, Since pivoting to prioritize the development of NPM-115 for chronic weight managemen...
Sources:
Vivani Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vivani Medical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vivani Medical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
